MicroRNAs Expression Profiles in Cardiovascular Diseases

Table 1

Circulating miRNAs as diagnostic markers for CAD.

miRNAs	Regulation	Groups	Source	Methods	Reference
miR-126, -17, -92a, -145, -155	Down	Human/36 CAD,	Plasma or	Array	[83]
miR-133, -208a	Up	17 controls	Serum
miR-92a, -126, -133a,	Up ACS versus CAD	Human/31 CAD, 19 ACS;	Plasma	qRT-PCR	[78]
-208a, -499		7 controls
miR-140-3p, miR-182	Up	Human/12 CAD, 12 controls	Whole blood	Array	[89]
miR-19a, -484, -155, -222,	Down	Human/10 CAD, 15 controls	Whole blood	Array	[84]
miR-29a, -378, -342, -181d,				qRT-PCR
miR, 145, -150, -30e-5p
miR-221, -222	Up	Human/44 CAD, 22 non-CAD	PBMCs	qRT-PCR	[86]
miR-146a/b	Up	Human/66 CAD, 33 non-CAD	PBMCs	qRT-PCR	[88]
miR-19, -21, -146, -155, -133	Up ACS versus CAD	Human/5 CAD, 5 non-CAD	Plasma MPs	qRT-PCR	[74]
miR-135a	Up versus controls	Human/25 UAP;	PBMCs	Array	[73]
miR-147	Down versus controls	25 stable SAP; 20 controls
miR-134, -198, -370	Up UAP versus SAP
miR-1, -126, -485-3p cluster; miR-1, -133a, -126 cluster	Up SA versus controls; Up in UA versus controls	Human/53 CAD: 34 SA, 19 UA, 20 controls	Plasma	qRT-PCR	[75]
miR-337-5p; miR-145	Up SA versus controls; Up in UA versus controls
miR-106b/25 cluster, -17/92a cluster,	Up CAD versus controls	Human/134 CAD: 31 SA, 45 UA, 37 controls	Plasma	qRT-PCR	[156]
-21/590-5p family, -126*, -451
miR-106b, -25, -92a, -21, -590-5p, -126*	Up UA versus controls	Human/ 5 UA, 5 controls	Plasma MPs	qRT-PCR
miR-340*, -624*	Up	Human/12 premature CAD,; 12 controls	Platelets	Array	[77]
		Human/40 CAD, 40 controls	Platelets	qRT-PCR

ACS: acute coronary syndrome; AP: angina pectoris; CAD: coronary artery disease; CHF: congestive heart failure; CVD: cardiovascular disease; Down: downregulated; miR: microRNA; MPs: microparticles; PBMCs: peripheral blood mononuclear cells; qRT-PCR: quantitative real-time polymerase chain reaction; SA: stable angina; SAP: stable angina pectoris; UA: unstable angina; UAP: unstable angina pectoris; Up: upregulated.